News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
LINDIS Biotech receives Positive CHMP Opinion for KORJUNY® (catumaxomab) in the European Union
LINDIS Biotech receives Positive CHMP Opinion for KORJUNY® (catumaxomab) in the European Union, becoming the only drug approved for intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas